Background: The long noncoding RNA (lncRNA) highly up-regulated in liver cancer (HULC) was identified as an oncogenic noncoding RNA that contributed to hepatocellular carcinoma (HCC) progression. Generally, lncRNAs have been shown to act as a sponge for microRNAs, hindering them from performing their actions. Recent study has shown that HULC sequester miR-186, meanwhile its expression was repressed by it. Our bioinformatics revealed that miR-186 targets HULC and the insulin-like growth factor 2-mRNA-binding protein-1 (IGF2BP1) which was shown to degrade HULC and to stabilize IGF1R in HCC. Therefore, we aimed at investigating the impact of miR-186 on IGF2BP1 and hence on HULC in liver cancer in attempt to unravel the underlying mechanism by which HULC enhances hepatocarcinogenesis. Methods: A total of 18 HCC and 13 healthy liver biopsies were used. Screening and correlation analysis were done. miR-186 expression was forced in Huh-7 cell lines. miR-186, HULC and IGF2BP1 were quantified by qRT-PCR. Binding confirmation and functional analysis experiments were performed. Results: The expression level of HULC was positively correlated with IGF2BP1 expression in HCC tissues, where both were highly elevated compared to healthy controls. However, miR-186 was significantly downregulated in HCC tissues and negatively correlated with IGF2BP1 expression. Furthermore, miR-186 had shown considerable tumor suppressor activity in HCC. Upon forcing miR-186 expression in HCC cell lines, IGF2BP1 expression was repressed, while in contrast to what was previously mentioned by Wang Y et.al, HULC expression showed no change. In addition, miR-186 showed direct binding on IGF2BP1, meanwhile it was bound to HULC on one of its two predicted binding sites. Thus, the binding of miR-186 to HULC without altering its expression may indicate that HULC act as a sponge for miR-186, thereby relieving IGF2BP1 and promoting hepatocarcinogenesis. Conclusions: HULC mediates its oncogenic action through sequestering the tumor suppressor miR-186, relieving its inhibitory effect on IGF2BP1 and thus promoting HCC progression. Finally, we suggest a novel lncRNA-microRNA-mRNA interaction to act as a novel target for halting HCC progression. Legal entity responsible for the study: German University in Cairo. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
87P Mir-506-3p synergistically represses breast cancer progression through altering cell cycle regulators Background: Mounting evidence demonstrated the potential of miR-506-3p to be employed in the diagnosis and treatment of a wide range of human malignancies due to its differential expression pattern and distinct biological roles. Despite the pivotal tumor suppressor role miR-506-3p plays in breast cancer (BC), it is frequently downregulated. Moreover, its role in governing cell cycle progression was not extensively studied in BC. Myc, E2F and Rb proteins are key players in cell cycle regulation. In BC, the CDK-RB-E2F axis is extensively deregulated by several genetic mutations. Additionally, the potent proto-oncogene Myc is highly expressed in BC. Thus, we aimed at uncovering the role miR-506-3p plays in cell cycle regulation in BC. Methods: pMyc-TA-Luc, pE2F-TA-Luc and pRb-TA-Luc vectors have response elements or enhancer elements of cMyc, Rb, and E2F cell cycle regulatory proteins, respectively. MDA-MB-231 cells were transfected with the aforementioned cell cycle vectors as well as an empty pLuc vector containing an unspecific binding site (used as a control) (Clontech, Germany). After 24 hrs, cells were co-transfected with miR-506-3p. Some cells were exposed to the transfection reagent only (mock cells). Relative luciferase activity was measured after 48 hrs by Steady-GloV R Luciferase Reporter Assay. Unspecific (baseline) luminescence detected for empty pTAL-Luc vector was subtracted from all values. Functional characterization of miR-506-3p was performed in MDA-MB-231 triple-negative breast cancer (BC) cells and MCF-7 HRþ cells to investigate its impact on several hallmarks of cancer using MTT and wound-healing assays. Results: Ectopic expression of miR-506-3p led to a significant decrease in cMyc and E2F proteins with a concomitant increase in RB protein compared to mock cells. Since miR-506-3p has seldomly been investigated in BC, the performed functional analysis of miRNA-506-3p revealed a significant decrease in the cellular viability and migration capacity of both MDA-MB-231TNBC cells and in MCF-7 HRþ BC cells. Conclusions: This study highlights a novel underlying mechanism of miR-506-3p as a tumor suppressor in BC through inhibiting cell cycle progression. This suggests its potential use in personalized BC therapy. Legal entity responsible for the study: German University in Cairo (GUC). Background: Hesperetin an aglycone extracted from citrus fruits, acts as a novel therapeutic agent in breast cancer (BC). TNBC patients showed the most heterogeneous molecular profiles portrayed with inferior overall survival. This highlights the emerging need of precision medicine to unravel the inter-wined molecular circuits in TNBC patients. Our group has uncovered the tumor suppressor activity of miR-486-5p in liver cancer and BC. However, its role in tuning the metastatic behaviour of TNBC cells remains to be unveiled. This study aims at investigating the interplay of hesperitin and miR-486-5p as a novel therapeutic approach towards achieving a personalized treatment code for TNBC patients. 
